All In Biotech

Drug Trial Radar · NCT07211152

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women

A Phase Ⅲ, Randomized, Double-blind, Positive Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of an Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Oct 13, 2025

Primary completion

Jun 26, 2026

Study completion Jun 26, 2026

Sponsor

Lead sponsor
Sinovac Biotech Co., LtdIndustry
Sponsor type
Industry
First posted
Oct 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 39 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, positive controlled phase Ⅲ clinical trial to assess the immunogenicity and safety of Sinovac QIV in pregnant women. A total of 150 healthy pregnant women aged 18\~39 years at 20 to 32 weeks of pregnancy will be enrolled. All participants will be randomized to test group and control group in a ratio of 2:1 and receive one dose of vaccine (0.5 mL) of Sinovac QIV or Vaxigrip QIV, respectively. Blood samples will be collected from participants prior to vaccination and 28 days after vaccination. Moreover, to evaluate trans-placental antibodies, blood samples at the end of the gestation period (delivery) and the cord blood sample will be collected, if applicable. For safety assessment, any immediate adverse events within 30 minutes, solicited local and systemic adverse events within 7 days and unsolicited adverse events within 28 days will be collected. Serious adverse events will be collected within 8 weeks after delivery. Pregnancy and birth outcomes will be collected as well.

Conditions

  • Influenza

Interventions

  • Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIVBiological

    Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

  • Vaxigrip QIVBiological

    Participants will receive one dose of vaccine (0.5 mL) of Vaxigrip QIV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The seroconversion rates (SCRs) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after vaccination.Time frame: 28 days after vaccination
  2. The seroprotection rates (SPRs) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after vaccination.Time frame: 28 days after vaccination
  3. The geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after vaccination.Time frame: 28 days after vaccination
  4. The geometric mean increase (GMI) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after vaccination.Time frame: 28 days after vaccination
  5. Incidence of adverse reactions within 28 days after vaccinationTime frame: 28 days after vaccination

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Health Cube Medical Clinics

    Mandaluyong, National Capital Region, Philippines

  • University of the Philippines - Philippine General Hospital (UP-PGH)

    Manila, National Capital Region, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.